Study drug for adults with cystic fibrosis lung disease
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This Phase 2 trial tests 4D-710 to improve lung health in adults with cystic fibrosis who either cannot take CFTR modulator medicines or are not doing well enough on them. You may be eligible if you have moderate lung function and stable oxygen levels, and you meet other safety and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have confirmed cystic fibrosis, with specific CF lab findings and/or CFTR gene changes
- Your lung test (FEV1) is between 50% and 90% predicted (main study) or between 40% and under 70% predicted (sub-study)
- Your oxygen level is at least 92% when resting on room air
- You either cannot take CFTR modulator therapy, or (for the sub-study) you are on it at a stable dose for at least 60 days
- You cannot currently have certain lung infections, smoking/vaping, or conditions that make steroid treatment unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This early study tests an individualized approach (“theratyping”) to match your cystic fibrosis (CF) to the CFTR medicine that may work best for your specific genetic change. It may help find a more tailored treatment plan and see how your body responds, while using medicines that are already approved for some people with CF.
This study looks at whether starting airway clearance techniques (like exercises or devices to clear mucus from the lungs) earlier in the day works better for children with cystic fibrosis who are already taking a CFTR modulator medication. It aims to find a simple, effective routine to help keep lungs healthy.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
This study looks at how where your body stores fat may be linked to changes in metabolism and lung function over time in people with cystic fibrosis. It also compares results with healthy people similar in age, sex, and body size to understand the differences better.
Hear when a new Cystic Fibrosis Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.